Skip to main content

Principles of Fistula Repair

Fistula repair requires control of infection, definition of anatomy, optimization and a reconstruction appropriate to the tissue and organs involved. Urinary, bowel and vascular-urinary fistulae differ substantially. Suspected ureteroarterial fistula with major hematuria warrants urgent vascular assessment and hemorrhage control before urinary reconstruction.[32][1][2][3][4]

Why Fistulae Persist​

Four classical mechanisms prevent spontaneous healing of a fistula:[5]

  1. Distal obstruction maintaining flow through the tract
  2. Foreign body or calculus physically blocking closure (suture material, ureteral stent, mesh)
  3. Granulomatous tissue or malignancy in the tract (TB, Crohn's disease, cancer)
  4. Epithelialization of the tract: the fistula develops its own lining and becomes self-sustaining

A fifth, increasingly recognized in pelvic reconstruction, is radiation-induced tissue ischemia, in which irradiated tissue has poor vascularity and impaired healing capacity.[6][7]

The mnemonic FRIEND captures the same ideas for enterocutaneous fistulae and provides a useful checklist for some urinary fistulae: Foreign body, Radiation, Infection or inflammation, Epithelialization, Neoplasm, Distal obstruction.[3][8]

Phased Management​

Recognition, resuscitation and source control​

Treat sepsis, drain collections, relieve obstruction and replace fluid and electrolyte losses when present. Use antimicrobials for infection, with cultures and source control guiding treatment. Skin protection and controlled effluent collection are particularly important for external bowel fistulae. Urinary drainage may use a bladder catheter, ureteral stent or nephrostomy according to the level of the leak.[1][2][11]

In a 1978 external gastrointestinal fistula cohort, 68% of deaths occurred with uncontrolled sepsis.[9] The high-output threshold of 500 mL/day is used in enterocutaneous fistula care.[3][9]

Define anatomy and optimize​

Select imaging and endoscopy to establish the involved organs, obstruction, collections and tissue condition. Assess nutrition and functional reserve individually. Patients with enterocutaneous fistulae can have substantial protein, fluid and electrolyte losses; specialist nutrition support may include enteral feeding, fistuloclysis or parenteral nutrition according to anatomy and tolerance.[2][3][4][10]

Low albumin was associated with mortality in a postoperative enterocutaneous fistula cohort, but a threshold of 3.0 g/dL is not a nutritional diagnosis or a stand-alone clearance target for repair.[13]

Reassess the need for definitive treatment​

Persistence despite drainage and correction of reversible factors prompts a reconstructive assessment. No fixed 4–6-week interval applies; timing depends on tissue recovery. Particularly after an open abdomen or enteroatmospheric fistula, definitive reconstruction may need to wait until recovery and wound healing. Timing depends on tissue condition, sepsis, anatomy and the patient's goals.[10][23][30]

Factors Predicting Spontaneous Closure​

Foreign material, distal obstruction, active infection or inflammation, malignancy, radiation injury and an epithelialized tract can make spontaneous healing less likely.[5][8][14] Prediction is anatomy-specific:

  • Enterocutaneous fistulae: high output, jejunal origin, multiple tracts and sepsis were adverse factors in a 174-patient postoperative cohort. Tract length and intestinal continuity also matter.[9][13]
  • VVF: a recent, small defect with viable tissue may merit a trial of bladder drainage; closure is uncommon overall and the evidence is mainly retrospective.[26]
  • Ureterovaginal fistula: early stenting can succeed in selected cases. A meta-analysis of 17 retrospective studies reported 32% pooled success for endoscopic stenting in the 12 studies reporting that approach, with substantially different results by timing.[18]

Approach Selection​

Choose the exposure that permits safe access, ureteral protection and a tension-free repair. Selected high fistulae are accessible vaginally. An abdominal approach may be needed for inaccessible defects or ureteral reimplantation.[17][26]

Use the separate female, male and all-patient atlases for anatomy-specific options. Extensive tissue loss, irradiation, associated outlet disease and prior repairs may require vascularized tissue, staged reconstruction or diversion.[1][2]

A 2024 systematic review included 46 studies of vesicovaginal, urethrovaginal and bladder neck–vaginal fistulas; its 17 nonrandomized VVF vaginal-versus-abdominal-laparotomy comparisons (n=1,143) found insufficient evidence to determine a difference in reported repair success (RR 0.98, 95% CI 0.94–1.03). Interposition, edge trimming, fibrin glue and fascial sling showed no statistically significant improvement in fistula closure in the available comparisons.[31]

Timing​

Older practice often delayed urinary-fistula repair for several months to let inflammation settle. Current EAU guidance individualizes timing once edema, inflammation, necrosis and infection have resolved; no fixed waiting period fits all patients.[15][26]

Recent observational reports support feasibility of selected early repairs:

  • Adinata's 2026 retrospective series of 80 women defined early transvaginal VVF repair as less than four weeks, not less than three months. Its higher early-group success was not a randomized noninferiority comparison.[16]
  • In Zhang's 2026 VVF subgroup, longer delay was associated with failure (12 versus 6 months); confounding by complexity and referral history prevents concluding that delay itself caused failure.[6]
  • The ureterovaginal meta-analysis found 95% pooled success for stenting within two weeks versus 20% after six weeks, but every included study was retrospective. Prompt recognition and drainage are reasonable.[18]

Tension-free Closure and Tissue Preservation​

Aim for viable tissue, adequate mobilization, secure closure and appropriate drainage. For bladder repairs, test watertightness without overdistending the reconstruction. Separate adjacent organ repairs and offset suture lines where feasible.[1][26]

The 2026 Cochrane publication is a review protocol and not a completed comparative review; its background describes one- or two-layer bladder closure.[19]

Remove foreign material and nonviable tissue, while preserving tissue needed for closure. Latzko repair closes selected apical defects without formal excision, and EAU’s review of a trimming trial did not establish better closure from trimming.[19][26]

For enterocutaneous fistula surgery, a 205-patient retrospective series found more recurrence after oversewing or wedge repair than resection and reanastomosis (36% versus 16%).[11]

Tissue Interposition​

Vascularized tissue can separate closures and supplement a compromised bed. Consider it for selected recurrent, irradiated or tissue-deficient repairs. Evidence for routine interposition in simple VVF is limited.[7][26]

TissueCommon usePlanning considerations
Martius fat padVaginal or urethral repairsReach, pedicle integrity, labial wound and sensory effects
OmentumAbdominal or combined pelvic repairsAvailable length, prior operations and abdominal morbidity
GracilisComplex perineal or rectourinary repairsVascular supply, reach and donor morbidity
PeritoneumSelected abdominal VVF repairsLocal tissue quality and a tension-free pedicle

Technique-specific pages give the relevant cohorts and limitations. For recurrent or otherwise complex RVF, ASCRS typically recommends a gracilis or bulbocavernosus (Martius) flap ; the guideline does not prescribe a fixed sequence.[20]

Diversion and Stenting​

Provide reliable low-pressure drainage suited to the repair. After ureteric fistula repair, use anatomical and functional imaging to detect stricture and deterioration in renal function.[26] Nephrostomy is an appropriate planned option for upper-tract leakage or failed retrograde drainage.[1][18]

Postoperative bladder-catheter duration varies by repair:

  • WHO: 7–10 days after selected simple obstetric urinary fistula repairs.[27]
  • IUGA/ICS 2026 obstetric consensus: a Delphi consensus of fistula surgeons (statement 37) sets a minimum of 10–14 days of continuous drainage after obstetric VVF repair. The group acknowledges WHO's 7–10 days and that 7 days may suffice for simple cases.[28]
  • EAU 2026 : expert opinion suggests 10–14 days for simple or postsurgical VVF and 14–21 days for complex or postradiation repair.[26]

Use the operative findings, drainage function and assessment for persistent leakage to plan removal. For RVF endorectal advancement-flap repair, ASCRS advises individualizing diversion because a stoma has not been shown to significantly improve outcomes; it generally recommends a diverting ostomy with Martius or gracilis flap repair despite limited supporting evidence.[20] In a retrospective series of 30 men with RUF, selective fecal diversion was possible.[33]

Pharmacologic Adjuncts — Somatostatin and Octreotide​

Somatostatin analogues have been studied to reduce gastrointestinal fistula secretions.[3][21][22] Older reviews and ASPEN-FELANPE guidance were more favorable about closure.[3][21][22]

A 2025 meta-analysis of nine randomized trials (442 participants) found no statistically significant increase in closure across seven trials: 134/193 versus 99/170 with standard care (RR 1.11, 95% CI 0.95–1.28).[29] Time to closure was about six days shorter in the trials reporting that outcome; mortality, complications and need for surgery did not differ significantly. Regimens and fistula types varied, and certainty was mostly low. The meta-analysis did not pool measured output reduction. One included open-label randomized trial enrolled 40 adults (17 with intestinal fistulas and 23 with small-bowel enterostomies); for the eight-week primary endpoint, 9/20 assigned to lanreotide and 2/20 controls had at least 25% output reduction in the intention-to-treat analysis using last observation carried forward.[34] These data suggest a possible output-management adjunct for selected high-output intestinal losses.[29][34]

Negative Pressure Wound Therapy (NPWT / VAC)​

For an open abdominal wound with an enteroatmospheric fistula, the immediate goals are effluent isolation, protection of exposed bowel and wound healing. NPWT can help achieve those goals, but should not be applied directly to exposed viscera. Definitive fistula reconstruction is usually delayed until recovery and wound healing.[30]

An older review of ten level-IV studies including 151 patients reported a median study-level VAC closure rate of 64.6%.[12] In a later 77-patient enteroatmospheric series, 14 healed without surgery and 56 required intestinal reconstruction.[23]

Radiation-Bed Considerations​

Radiated tissue is non-compliant, hypovascular, and slow to heal. A fistula arising after radiotherapy as primary cancer treatment may indicate tumour recurrence; assess for recurrence before reconstruction.[26] Radiation-associated fistula planning includes:

  • EAU recommends an interposition graft when repairing a radiation-associated fistula . Use suitable non-irradiated tissue when repair is feasible; some patients need diversion instead. When urinary or fecal diversion is required, EAU recommends avoiding an irradiated bowel segment .[7][26]
  • Staged reconstruction may be needed, with optimization rather than closure as the first step.
  • Pre-operative counseling covers the higher failure rates and the fact that permanent dual diversion is a legitimate reconstructive outcome for the most hostile cases.
  • In the VVF subgroup (39 patients) of a 67-patient mixed urogenital fistula series, failure was reported in 75% with prior radiotherapy versus 10.8% without it; the irradiated subgroup size and referral case mix limit generalization.[6]

The Failed Repair​

After a failed repair, the sequence is:

  1. Confirm the diagnosis.
  2. Image the tract.
  3. Reassess the tissue bed.
  4. Decide whether the next operation adds what the previous one lacked: better approach, vascularized flap, protective diversion, or simply more time.
  5. Obtain patient agreement that further attempts are reasonable.

Escalating to permanent dual diversion is sometimes the correct next step rather than another attempt at closure.

For obstetric fistula, the IUGA/ICS 2026 consensus considers a fistula incurable only after three failed repairs despite adequate technique and postoperative care, with independent assessment by two expert surgeons (statements 7 and 38). Diversion can be offered to these women, weighing device availability, acceptance and long-term follow-up.[28]

Interpreting Outcomes​

Report anatomical closure, continence, complications, quality of life and reoperation separately. When reporting outcomes, identify the fistula type, etiology, prior repairs, denominator and follow-up. The cited IUGA/ICS consensus defines success specifically after obstetric urinary pelvic floor fistula repair.[28]

  • The IUGA/ICS 2026 consensus for obstetric fistula defines surgical success as anatomical closure without residual urinary incontinence (statement 3). After obstetric urinary fistula repair, residual urinary leakage does not meet the IUGA/ICS consensus definition of cure; the consensus recommends a dye test at catheter removal (statement 2) and at least 10–14 days of continuous catheter drainage (statement 37). A fistula that breaks down within 3–6 months is counted as a failed repair rather than a new fistula (statement 15, near consensus). These are expert consensus statements for obstetric fistula.[28]

  • Zhang's 67-patient mixed GU-fistula cohort reported 80.6% success after first repair and 92.5% ultimately; VVF success was 89.7%.[6]

  • Singh's 638-patient mixed GU cohort reported first-repair success at three months—cure of urinary incontinence with complete restoration of bladder and vaginal function—of 93.95%, 94.24% and 96.55% in selected abdominal, vaginal and laparoscopic groups.[24]

  • Historical external gastrointestinal or enterocutaneous cohorts reported spontaneous closure of 32%[9] and 37%[13], respectively, and substantial sepsis-related morbidity.[9][13]

  • In Crohn-related anorectal fistulae, treatment combines control of sepsis and luminal and perianal inflammation with appropriate medical and surgical therapy. Drain an abscess before relying on immune-directed treatment or definitive closure.[20][25]

Practical Checklist​

PrincipleApplication
Control infection and lossesDrain collections, treat infection, relieve obstruction and replace losses appropriate to the fistula.
Assess nutrition and reserveIndividualize support; do not use an albumin target or an ECF feeding prescription for every GU fistula.
Define anatomyEstablish involved organs, tissue condition, obstruction and associated disease.
Preserve viable tissueRemove foreign material and nonviable tissue; avoid unnecessary tissue sacrifice.
Plan exposure and closureAim for a tension-free repair with secure organ closure; layers and interposition depend on anatomy.
Plan drainage and follow-upSpecify catheter/stent function, duration, assessment before removal and the patient's functional goals.
Individualize timingUse recovery, tissue condition and the consequences of waiting; no universal calendar interval applies.

These principles require the anatomy-specific guidance and evidence limitations described above.[1][3][20][26][28]

See Also​

Videos​

Urinary Fistula
Urology resident didactics (2020)
Urinary Tract Fistulas
AUGS FPMRS Fellows Webinar (2020)

References​

1. Wei N, Pfeuti C, Linder BJ. "Contemporary Genitourinary Fistula Management: Treatment, Trends, and Innovations." Curr Opin Obstet Gynecol. 2025. doi:10.1097/GCO.0000000000001065

2. Mellano EM, Tarnay CM. "Management of Genitourinary Fistula." Curr Opin Obstet Gynecol. 2014;26(5):415–423. doi:10.1097/GCO.0000000000000095

3. Kumpf VJ, de Aguilar-Nascimento JE, Diaz-Pizarro Graf JI, et al. "ASPEN-FELANPE Clinical Guidelines: Nutrition Support of Adult Patients With Enterocutaneous Fistula." JPEN J Parenter Enteral Nutr. 2017;41(1):104–112. doi:10.1177/0148607116680792

4. Polk TM, Schwab CW. "Metabolic and Nutritional Support of the Enterocutaneous Fistula Patient: A Three-Phase Approach." World J Surg. 2012;36(3):524–533. doi:10.1007/s00268-011-1315-0

5. Jones J, Aboumarzouk OM. "Fistulae and Sinuses." Chapter 24.

6. Zhang C, Saussine C, Tricard T. "Urogenital Fistulas: Surgical Management, Outcomes, and Prognostic Factors: A 14-Year Monocentric Experience." Int Urogynecol J. 2026. doi:10.1007/s00192-026-06580-0

7. Kapriniotis K, Loufopoulos I, Gresty HCM, Greenwell TJ, Ockrim JL. "The Utility of Martius Fat Pad in the Repair of Urogenital Fistulae: Review of Current Evidence." BJU Int. 2024;134(3):365–374. doi:10.1111/bju.16350

8. Pfeifer J, Tomasch G, Uranues S. "The Surgical Anatomy and Etiology of Gastrointestinal Fistulas." Eur J Trauma Emerg Surg. 2011;37(3):209–213. doi:10.1007/s00068-011-0104-7

9. Reber HA, Roberts C, Way LW, Dunphy JE. "Management of External Gastrointestinal Fistulas." Ann Surg. 1978;188(4):460–467. doi:10.1097/00000658-197810000-00003

10. Lloyd DA, Gabe SM, Windsor AC. "Nutrition and Management of Enterocutaneous Fistula." Br J Surg. 2006;93(9):1045–1055. doi:10.1002/bjs.5396

11. Lynch AC, Delaney CP, Senagore AJ, et al. "Clinical Outcome and Factors Predictive of Recurrence After Enterocutaneous Fistula Surgery." Ann Surg. 2004;240(5):825–831. doi:10.1097/01.sla.0000143895.17811.e3

12. Misky A, Hotouras A, Ribas Y, Ramar S, Bhan C. "A Systematic Literature Review on the Use of Vacuum Assisted Closure for Enterocutaneous Fistula." Colorectal Dis. 2016;18(9):846–851. doi:10.1111/codi.13351

13. Martinez JL, Luque-de-Leon E, Mier J, Blanco-Benavides R, Robledo F. "Systematic Management of Postoperative Enterocutaneous Fistulas: Factors Related to Outcomes." World J Surg. 2008;32(3):436–443. doi:10.1007/s00268-007-9304-z

14. Lunniss PJ, Sheffield JP, Talbot IC, Thomson JP, Phillips RK. "Persistence of Idiopathic Anal Fistula May Be Related to Epithelialization." Br J Surg. 1995;82(1):32–33. doi:10.1002/bjs.1800820112

15. Lee RA, Symmonds RE, Williams TJ. "Current Status of Genitourinary Fistula." Obstet Gynecol. 1988;72(3 Pt 1):313–319.

16. Adinata Y, Hudaya S, Hutasoit YI, et al. "Prognostic Factors of Transvaginal Repair for Vesicovaginal Fistulas: A 5-Year Single-Center Study." Int Urogynecol J. 2026. doi:10.1007/s00192-026-06561-3

17. Wang Y, Hadley HR. "Nondelayed Transvaginal Repair of High Lying Vesicovaginal Fistula." J Urol. 1990;144(1):34–36. doi:10.1016/s0022-5347(17)39359-x

18. Bahuguna G, Panwar VK, Mittal A, et al. "Management Strategies and Outcome of Ureterovaginal Fistulae: A Systematic Review and Meta-Analysis." Neurourol Urodyn. 2022;41(2):562–572. doi:10.1002/nau.24874

19. Okada Y, Matsushita T, Hasegawa T, et al. "Surgical Interventions for Treating Vesicovaginal Fistula in Women." Cochrane Database Syst Rev. 2026;1:CD015413. Protocol. doi:10.1002/14651858.CD015413

20. Gaertner WB, Burgess PL, Davids JS, et al. "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula." Dis Colon Rectum. 2022;65(8):964–985. doi:10.1097/DCR.0000000000002473

21. Rahbour G, Siddiqui MR, Ullah MR, et al. "A Meta-Analysis of Outcomes Following Use of Somatostatin and Its Analogues for the Management of Enterocutaneous Fistulas." Ann Surg. 2012;256(6):946–954. doi:10.1097/SLA.0b013e318260aa26

22. Coughlin S, Roth L, Lurati G, Faulhaber M. "Somatostatin Analogues for the Treatment of Enterocutaneous Fistulas: A Systematic Review and Meta-Analysis." World J Surg. 2012;36(5):1016–1029. doi:10.1007/s00268-012-1494-3

23. Wainstein DE, Calvi RJ, Rezzonico F, et al. "Management of Enteroatmospheric Fistula: A Ten-Year Experience Following Fifteen Years of Learning." Surgery. 2023;173(4):1079–1085. doi:10.1016/j.surg.2022.12.001

24. Singh V, Bhandari K, Mandal S, et al. "Evolving Surgical Strategies for Management of Genitourinary Fistula Repair Over 25 Years: Insights From a Paradigm Shift." Int J Gynaecol Obstet. 2026;173(1):283–295. doi:10.1002/ijgo.70598

25. Scharl M, Rogler G, Biedermann L. "Fistulizing Crohn's Disease." Clin Transl Gastroenterol. 2017;8(7):e106. doi:10.1038/ctg.2017.33

26. European Association of Urology. Non-neurogenic Female LUTS guideline, section 4.8: urinary fistula. 2026 edition. Full guideline section.

27. World Health Organization. WHO recommendation on duration of bladder catheterization after surgical repair of simple obstetric urinary fistula. 2018. Official recommendation summary.

28. Maljaars LP, Corcos J, Ghoniem G, et al. Consensus statements on the definition of surgical success following obstetric urinary pelvic floor fistula repair: an IUGA-ICS proposal. Int Urogynecol J. 2026. doi:10.1007/s00192-025-06413-6. Original consensus paper.

29. Ribeiro Junior MAF, Vieira LF, Thalib HI, et al. Somatostatin-based therapies for external gastrointestinal fistulas: updated meta-analysis of randomized clinical trials. World J Gastrointest Pharmacol Ther. 2025;16(4):111889. doi:10.4292/wjgpt.v16.i4.111889.

30. Coccolini F, Roberts D, Ansaloni L, et al. The open abdomen in trauma and non-trauma patients: WSES guidelines. World J Emerg Surg. 2018;13:7. doi:10.1186/s13017-018-0167-4.

31. Thompson JC, Halder GE, Jeppson PC, et al. Repair of vesicovaginal fistulae: a systematic review. Obstet Gynecol. 2024;143(2):229–241. doi:10.1097/AOG.0000000000005468.

32. Ebata Y, Morisaki K, Matsubara Y, et al. "A systematic review of management of ureteroarterial fistula." J Vasc Surg. 2022;76(5):1417-1423.e5. doi:10.1016/j.jvs.2022.05.015

33. Keller DS, Aboseif SR, Lesser T, et al. "Algorithm-based multidisciplinary treatment approach for rectourethral fistula." Int J Colorectal Dis. 2015;30(5):631-638. doi:10.1007/s00384-015-2183-0

34. Timmer AS, de Vries F, Gans SL, et al. "Clinical trial: The effectiveness of long-acting somatostatin analogue for output reduction of high-output intestinal fistula or small bowel enterostomy. A randomised controlled trial." Aliment Pharmacol Ther. 2024;60(6):727-736. doi:10.1111/apt.18166